Eli Lilly vs Merck & stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Eli Lilly is more profitable, grows faster and has less debt. Merck & is cheaper for its profits.
Side by side
| Eli Lilly | Merck & | |
|---|---|---|
| $1.20 trillion | $330 billion | |
| 31.7% | 28.1% | |
| +21.6% | +9.4% | |
| 58.1× | 18.1× | |
| 1.1 years | 1.2 years | |
| 34.8% | 17.8% | |
| 0.6% | 2.8% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Eli Lilly vs Merck KGaA · Eli Lilly vs Moderna · Eli Lilly vs Natera · Eli Lilly vs Novo Nordisk · Merck & vs McKesson · Merck & vs Merck KGaA · Merck & vs Moderna · Merck & vs Pfizer

